Source: South China Morning Post [Hong Kong]
“France will reimburse the cost of weight-loss drugs prescribed to severely obese patients from mid-June in a first for a European Union country, Health Minister Stephanie Rist said on Thursday. Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro medications have led a boom in anti-obesity treatment, attracting interest from governments keen to address rising overweight levels worldwide. Rist estimated the annual cost to the state at around €100 million (US$116 million) at full roll-out. Patients in France are currently paying around €300 per month on average for the drugs, she said, without indicating how many people currently follow such treatments.” (05/28/26)